Eilsberger Friederike, Kreissl Michael C, Reiners Christoph, Holzgreve Adrien, Luster Markus, Pfestroff Andreas
Department of Nuclear Medicine, University Hospital Marburg, 35043 Marburg, Germany.
Department of Radiology and Nuclear Medicine, Nuclear Medicine, Division of Nuclear Medicine, University Hospital Magdeburg, 39120 Magdeburg, Germany.
Biomedicines. 2023 Mar 15;11(3):911. doi: 10.3390/biomedicines11030911.
The American Thyroid Association (ATA) uses criteria to assess the risk for persistent disease in differentiated thyroid carcinoma (DTC) after radioiodine therapy (RAI). There are no data available showing that this classification can be adopted unadjusted by Germany.
The aim of our study is to investigate whether the ATA classification can be applied to a German population for short-term prognosis. Furthermore, we investigated the influence of an age cutoff value.
We retrospectively analyzed 121 patients who were referred to our tertiary referral center. Patients were classified into risk categories, and the therapy response was determined according to ATA.
A total of 73/83 (88%) ATA low-risk patients and 12/19 (63%) intermediate-risk patients showed an excellent response; 2/19 (11%) high-risk patients had a biochemical, and 6 (31%) had a structural incomplete response. Of all 39 patients ≥55 years, 84% had an excellent response. Using a cut off of 50 years, 50/62 (81%) of the older patients showed an excellent response.
The ATA risk classification is able to estimate the response to RAI therapy in a German population. A shift from 55 to 50 years as an age cutoff value does not result in any relevant change in the treatment response.
美国甲状腺协会(ATA)采用标准来评估分化型甲状腺癌(DTC)患者接受放射性碘治疗(RAI)后疾病持续存在的风险。目前尚无数据表明德国可直接采用这一分类方法。
本研究旨在调查ATA分类是否可应用于德国人群以评估短期预后。此外,我们还研究了年龄临界值的影响。
我们回顾性分析了转诊至我们三级转诊中心的121例患者。根据ATA将患者分为不同风险类别,并确定治疗反应。
共有73/83(88%)例ATA低风险患者和12/19(63%)例中风险患者治疗反应良好;2/19(11%)例高风险患者出现生化不完全反应,6例(31%)出现结构不完全反应。在所有39例年龄≥55岁的患者中,84%治疗反应良好。以50岁为临界值,62例老年患者中有50/62(81%)治疗反应良好。
ATA风险分类能够评估德国人群对RAI治疗的反应。将年龄临界值从55岁调整为50岁不会导致治疗反应出现任何相关变化。